Pinki Rawat, Saurabh Manaswita Verma


Objective: The objective of the present study is to perform the molecular docking studies of some newly designed chroman analogs on estrogen
receptor (ER) (PDB: 1YIM) by Glide v5.0.
Methods: The docking studies of designed chroman analogs were performed on the active site of ER (PDB: 1YIM) for anti-breast cancer activity using
Schrodinger Glide v5.0. Absorption, distribution, metabolism, excretion properties of all designed compounds were also calculated by Qik Prop v3. 0.
Results: Among all compounds, compound 38 showed highest docking score (−8.17) in the series. Docking scores were compared with standard
drugs tamoxifene (−11.08) and anastrazole (−7.86). All compounds were found to be within expectable range for percent human oral absorption,
octanol/water partition coefficient (QP log Po/w), brain/blood partition coefficient (QP log BB), total solvent accessible surface area, and rule of five
predicted by Qikprop.
Conclusion: Most of the compounds in the series showed good molecular docking score on the ER (PDB: 1YIM). Compound 38 (−8.16) exhibited
better docking score than standard drug anastrazole (−7.86). Most of the pharmacokinetic properties conducted by Qikprop were found to be within
the permissible range.
Keywords: Chroman, Docking, Estrogen receptor, Lipinski’s rule of five.

| PDF |


Purushothaman A, Nandhakumar E, Sachdanandam P. Anticancer effect

of shemamruthaa (a phytochemical formulation) on 7, 12-dimethylbenz

(a) anthracene induced mammary carcinoma in rats. Asian J Pharm Clin

Res 2012;5(1):101-7.

Bonfield K, Amato E, Bankemper T, Agard H, Steller J, Keeler JM, et al.

Development of a new class of aromatase inhibitors: Design, synthesis

and inhibitory activity of 3-phenylchroman-4-one (isoflavanone)

derivatives. Bioorg Med Chem 2012;20(8):2603-13.

Nam JM, Jeon KH, Kwon H, Lee E, Jun KY, Jin YB, et al.

Dithiiranylmethyloxy azaxanthone shows potent anti-tumor activity

via suppression of HER2 expression and HER2-mediated signals

in HER2-overexpressing breast cancer cells. Eur J Pharm Sci


Tan Q, Blizzard TA, Morgan JD nd, Birzin ET, Chan W, Yang YT, et al.

Estrogen receptor ligands. Part 10: Chromanes: Old scaffolds for new

SERAMs. Bioorg Med Chem Lett 2005;15(6):1675-81.

Gupta A, Dwivedy A, Keshri G, Sharma R, Balapure AK, Singh MM,

et al. Rapid synthesis of 4-benzylidene and 4-[bis-(4-methoxyphenyl)methylene-2-substituted


as potential selective


receptor modulators

(SERMs) using McMurry coupling



Med Chem Lett 2006;16(23):6006-12.

Reddy BV, Divya B, Swaina M, Rao TP, Yadav JS, Vardhan MV.

A domino Knoevenagel hetero-Diels–Alder reaction for the synthesis

of polycyclic chromene derivatives and evaluation of their cytotoxicity.

Bioorg Med Chem Lett 2012;22(5):1995-9.

Wang D, Chuang HC, Weng SC, Huang PH, Hsieh HY, Kulp SK, et

al. α-Tocopheryl succinate as a scaffold to develop potent inhibitors of

breast cancer cell adhesion. J Med Chem 2009;52(18):5642-8.

Miller WR. Aromatase inhibitors: Mechanism of action and role in the

treatment of breast cancer. Semin Oncol 2003;30:3-11.

Florence X, Dilly S, Tullio PD, Pirotte B, Lebrun P. Modulation

of the 6-position of benzopyran derivatives and inhibitory

effects on the insulin releasing process. Bioorg Med Chem


Conti C, Monaco LP, Desideri N. Design, synthesis and in vitro

evaluation of novel chroman-4-one, chroman, and 2H-chromene

derivatives as human rhinovirus capsid-binding inhibitors. Bioorg Med

Chem 2011;19(24):7357-64.

Koufaki M, Kiziridi C, Alexi X, Alexis MN. Design and synthesis of

novel neuroprotective 1,2 dithiolane/chroman hybrids. Bioorg Med

Chem 2009;17(17):6432-41.

Kanbe Y, Kim MH, Nishimoto M, Ohtake Y, Kato N, Tsunenari T,

et al. Discovery of thiochroman and chroman derivatives as pure

antiestrogens and their structure-activity relationship. Bioorg Med

Chem 2006;14(14):4803-19.

Lee H, Lee K, Jung JK, Cho J, Theodorakis EA. Synthesis and evaluation

of 6-hydroxy-7-methoxy-4-chromanone- and chroman-2-carboxamides

as antioxidants. Bioorg Med Chem Lett 2005;15(11):2745-8.

Shen Z, Ramamoorthy SP, Hatzenbuhler NT, Evrard DA, Childers W,

Harrison BL, et al. Synthesis and structure-activity relationship of

novel lactam-fused chroman derivatives having dual affinity at the

-HT1A receptor and the serotonin transporter. Bioorg Med Chem Lett


Kraus GA, Mengwasser J, Maury W, Oh C. Synthesis of

chroman aldehydes that inhibit HIV. Bioorg Med Chem Lett


Koufaki M, Kiziridi C, Papazafiri P, Vassilopoulos A, Varro A, Nagy Z,

et al. Synthesis and biological evaluation of benzopyran analogues

bearing class III antiarrhythmic pharmacophores. Bioorg Med Chem


Thompson R, Doggrell S, Hoberga JO. Potassium channel activators

based on the benzopyran substructure: Synthesis and activity of the C-8

substituent. Bioorg Med Chem 2003;11(8):1663-8.

Schrodinger LLC. New York, USA: Schrodinger Inc.; 2008. http://

Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT,

et al. Glide: A new approach for rapid, accurate docking and

scoring. Method and assessment of docking accuracy. J Med Chem


Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental

and computational approaches to estimate solubility and permeability

in drug discovery and development settings. Adv Drug Deliv Rev


About this article





Additional Links

Manuscript Submission


Asian Journal of Pharmaceutical and Clinical Research
Vol 8 Issue 6 (November - December) 2015 Page: 88-92

Print ISSN


Online ISSN



107 Views | 228 Downloads

Authors & Affiliations

Pinki Rawat
Department of Pharmaceutical Sciences & Technology, Birla Institute of Technology, Mesra, Ranchi-835215, Jharkhand, India

Saurabh Manaswita Verma

Article Tools

Email this article (Login required)
Email the author (Login required)


  • There are currently no refbacks.